JTT-705: Treatment of lipoprotein disorders cholesteryl ester transfer protein inhibitor

Drugs of the Future

Volumn 29, Issue 8, 2004, Pages 787-792

  Alegret, Marta ^a   Silvestre, Jordi S ^b   Castaner J ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL]ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; JJT 705; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; AORTA ARCH; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; INHIBITION KINETICS; LIPOPROTEIN DEFICIENCY; LIPOPROTEIN METABOLISM; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN SYNTHESIS INHIBITION; RABBIT; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

EID: 6344226742     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.08.827381     Document Type: Article

References (34)

1. Shinkai, H., Maeda, K., Yamasaki, T., Okamoto, H., Uchida, I. Bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. J Med Chem 2000, 43: 3566-72.
2. Shinkai, H., Maeda, K., Okamoto, H. (Japan Tobacco Inc.), CEPT activity inhibitors, EP 1020439, JP 1999049743, JP 1999222428, US 6426365, US 2003092708, US 6753346, WO 9835937.
3. Castelli, W.P., Garrison, R.J., Wilson, P.W., Abbott, R.D., Kalousdian, S., Kannel, W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA - J Am Med Assoc 1986, 256: 2835-8.
4. Keys, A. Coronary heart disease in seven countries. 1970, Nutrition 1997, 13: 250-2.
5. Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-9.
6. Sacks, F.M., Pfeffer, M.A., Moye, L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996, 335: 1001-9.
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998, 339: 1349-57.
8. Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H., Packard, C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995, 333: 1301-7.
9. Downs, J.R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D.R., Beere, P.A., Langendorfer, A., Stein, E.A., Kruyer, W., Gotto, A.M., Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA - J Am Med Assoc 1998, 279: 1615-22.
10. Gordon, D.J., Rifkind, B.M. High-density lipoprotein - The clinical implications of recent studies. New Engl J Med 1989, 321: 1311-6.
11. Gordon, D.J., Probstfield, J.L., Garrison, R.J., Neaton, J.D., Castelli, W.P., Knoke, J.D., Jacobs, D.R., Jr., Bangdiwala, S., Tyroler, H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79: 8-15.
12. Fielding, C.J., Fielding, P.E. Molecular physiology of reverse cholesterol transport J Lipid Res 1995, 36: 211-28.
13. Ji, Y., Jian, B., Wang, N., Sun, Y., Moya, M.L., Phillips, M.C., Rothblat, G.H., Swaney, J.B., Tall, A.R. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem 1997, 272: 20982-5.
14. Lawn, R.M., Wade, D.P., Garvin, M.R., Wang, X., Schwartz, K., Porter, J.G., Seilhamer, J.J., Vaughan, A.M., Oram, J.F. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999, 104: R25-31.
15. Yamashita, S., Hirano, K., Sakai, N., Matsuzawa, Y. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim Biophys Acta - Mol Cell Biol Lipids 2000, 1529: 257-75.
16. Barter, P.J., Brewer, H.B., Jr., Chapman, M.J., Hennekens, C.H., Rader, D.J., Tall, A.R. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23: 160-7.
17. Inazu, A., Brown, M.L., Hesler, C.B., Agellon, L.B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., Tall, A.R. Increased high-density lipoprotein levels caused by a common cholesterylester transferprotein gene mutation. New Engl J Med 1990, 323: 1234-8.
18. Hirano, K., Yamashita, S., Matsuzawa, Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol 2000, 11: 589-96.
19. Hirano, K., Yamashita, S., Kuga, Y. et al. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 1995, 15: 1849-56.
20. Hirano, K., Yamashita, S., Nakajima, N., Arai, T., Maruyama, T., Yoshida, Y., Ishigami, M., Sakai, N., Kameda-Takemura, K., Matsuzawa, Y. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 1997, 17: 1053-9.
21. Bruce, C., Sharp, D.S., Tall, A.R. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res 1998, 39: 1071-8.
22. Agerholm-Larsen, B., Nordestgaard, B.G., Steffensen, R., Jensen, G., Tybjaerg-Hansen, A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000, 101: 1907-12.
23. Moriyama, Y., Okamura, T., Inazu, A. et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 1998, 27: 659-667.
24. Sikorski, J.A., Connolly, D.T. The discovery of new cholesteryl ester transferprotein inhibitors. Curr Opin Drug Discov Dev 2001, 4: 602-13.
25. Sugano, M., Makino, N., Sawada, S., Otsuka, S., Watanabe, M., Okamoto, H., Kamada, M., Mizushima, A. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 1998, 273: 5033-6.
26. Rittershaus, C.W., Miller, D.P., Thomas, L.J. et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20: 2106-12.
27. Okamoto, H., Yonemori, F., Wakitani, K., Minowa, T., Maeda, K., Shinkai, H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000, 406: 203-7.
28. Clark, R.W., Sutfin, T.A., Ruggeri, R.B., Willauer, A.T., Sugarman, E.D., Magnus-Aryitey, G., Cosgrove, P.G., Sand, T.M., Wester, R.T., Williams, J.A., Perlman, M.E., Bamberger, M.J. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004, 24: 490-7.
29. Okamoto, H., Iwamoto, Y., Maki, M., Sotani, T., Yonemori, F., Wakitani, K. Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals. Eur J Pharmacol 2003, 466: 147-54.
30. de Grooth, G.J., Kuivenhoven, J.A., Stalenhoef, A.F., de Graaf, J., Zwinderman, A.H., Posma, J.L., van Tol, A., Kastelein, J.J. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: A randomized phase II dose-response study. Circulation 2002, 105: 2159-65.
31. Shimoji, E., Zhang, B., Fan, P., Saku, K. Inhibition of cholesteryl ster transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits. Atherosclerosis 2004, 172: 247-57.
32. Huang, Z., Inazu, A., Nohara, A., Higashikata, T., Mabuchi, H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (1979) 2002, 103: 587-94.
33. Kawano, K., Qin, S.-C., Lin, M., Tall, A.R., Jiang, X.-C. Cholesteryl ester transfer protein and phospholipid transfer protein have nonoverlapping functions in vivo. J Biol Chem 2000, 275: 29477-81.
34. Kobayashi, J., Okamoto, H., Otabe, M., Bujo, H., Saito, Y. Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. Atherosclerosis 2002, 162: 131-5.